Lansoprazole: Uses, Dosage & Side Effects
Proton Pump Inhibitor (PPI) — Reduces stomach acid production
Quick Facts About Lansoprazole
Key Takeaways About Lansoprazole
- Effective acid reducer: Lansoprazole blocks the proton pump in stomach cells, reducing acid production by up to 80–90% and providing sustained relief from heartburn, acid reflux, and peptic ulcers
- Convenient formulations: Available as orally disintegrating tablets that dissolve on the tongue without water, making it easier for patients who have difficulty swallowing capsules
- Important drug interactions: Lansoprazole can interact with methotrexate, warfarin, digoxin, theophylline, tacrolimus, ketoconazole, and certain HIV medications. Always inform your healthcare provider about all medications you take
- Take before meals: For best results, take lansoprazole at least 30 minutes before eating, preferably in the morning. Swallow capsules whole — do not crush or chew
- Long-term risks to monitor: Extended use may be associated with magnesium deficiency, vitamin B12 deficiency, increased fracture risk, and kidney inflammation. Regular medical review is important for long-term users
What Is Lansoprazole and What Is It Used For?
Lansoprazole is a proton pump inhibitor (PPI) that works by irreversibly blocking the hydrogen/potassium ATPase enzyme system (the proton pump) in stomach parietal cells. This reduces both basal and stimulated gastric acid secretion. It is used to treat heartburn, gastroesophageal reflux disease (GERD), peptic ulcers, Helicobacter pylori infection (in combination with antibiotics), and Zollinger-Ellison syndrome.
Lansoprazole belongs to the proton pump inhibitor (PPI) class of medications, which are among the most widely prescribed drugs worldwide. First approved in the early 1990s, lansoprazole has established itself as one of the leading treatments for acid-related gastrointestinal disorders. It is chemically classified as a substituted benzimidazole and is closely related to other PPIs such as omeprazole, pantoprazole, and esomeprazole.
Proton pump inhibitors work by targeting the final common pathway of gastric acid secretion in the parietal cells of the stomach lining. Unlike antacids, which simply neutralize acid already present in the stomach, or H2-receptor antagonists (such as ranitidine or famotidine), which block only one of several pathways stimulating acid production, PPIs like lansoprazole provide more complete and sustained acid suppression. A single daily dose of lansoprazole can reduce gastric acid output by approximately 80–90% over a 24-hour period.
Lansoprazole has a notable pharmacokinetic advantage: it demonstrates higher bioavailability (over 80%) compared to some other PPIs, meaning a greater proportion of the administered dose reaches the systemic circulation and is available to exert its therapeutic effect. It also has a relatively rapid onset of action, with measurable acid suppression beginning within 1–2 hours of oral administration.
The medication is available both over the counter (OTC) for short-term relief of frequent heartburn and by prescription for more serious or chronic conditions. The OTC formulation is intended for 14-day treatment courses, while prescription use may extend for several weeks or, in certain cases, long-term maintenance therapy under medical supervision.
Common Indications
Lansoprazole is approved for the treatment of a range of acid-related gastrointestinal conditions. The specific indications and recommended durations of treatment are as follows:
- Heartburn and acid reflux (OTC): Short-term treatment of frequent heartburn occurring 2 or more days per week. Self-treatment is limited to 14-day courses, and patients should consult a doctor if symptoms persist or recur after completing a course.
- Gastroesophageal reflux disease (GERD): Including erosive esophagitis (reflux esophagitis) and maintenance of healed esophagitis. Lansoprazole reduces the backflow of acid into the esophagus, relieving symptoms and promoting healing of the damaged esophageal lining.
- Duodenal ulcers: Short-term treatment of active duodenal (small intestine) ulcers, typically for 2–4 weeks. Lansoprazole promotes rapid healing by substantially reducing acid exposure to the ulcerated tissue.
- Gastric ulcers: Treatment of benign gastric (stomach) ulcers, typically for 4–8 weeks, including those associated with the use of nonsteroidal anti-inflammatory drugs (NSAIDs).
- Helicobacter pylori eradication: Used in combination with antibiotics (such as amoxicillin and clarithromycin, or clarithromycin and metronidazole) as part of triple therapy to eradicate H. pylori infection and heal associated ulcers. The standard regimen involves a 7-day course of treatment.
- NSAID-associated ulcer prophylaxis: Prevention and treatment of gastric and duodenal ulcers in patients who require long-term NSAID therapy for pain or inflammation and are at increased risk of ulcer development.
- Zollinger-Ellison syndrome: A rare condition involving excessive acid production due to gastrin-secreting tumors. Higher doses of lansoprazole (starting at 60 mg daily) may be required, and the dose is adjusted based on individual response.
Lansoprazole is a prodrug that is absorbed in the small intestine and then distributed to the parietal cells of the stomach. In the highly acidic environment of the parietal cell canaliculi (pH < 2), lansoprazole undergoes acid-catalyzed conversion to its active form, a sulfenamide derivative. This active metabolite then forms irreversible covalent disulfide bonds with cysteine residues on the proton pump enzyme (H+/K+-ATPase), permanently inactivating the pump. Because the inhibition is irreversible, acid secretion only resumes when new proton pump molecules are synthesized by the parietal cell, a process that typically takes 24–48 hours. This explains why the acid-suppressive effect of lansoprazole persists well beyond its relatively short plasma half-life of approximately 1.5 hours.
What Should You Know Before Taking Lansoprazole?
Before taking lansoprazole, you should be aware of contraindications, potential warnings, and situations that require medical advice. Lansoprazole can mask symptoms of serious conditions including gastric cancer, so new or worsening symptoms should always be evaluated by a healthcare provider. It is not suitable for immediate relief of occasional heartburn.
While lansoprazole is generally well-tolerated and has an established safety profile for short-term use, there are important considerations to understand before starting treatment. Being aware of these factors helps ensure that you use the medication safely and effectively, and that any potential risks are properly managed.
Contraindications
You should not take lansoprazole if:
- Allergy to lansoprazole or its ingredients: If you have a known hypersensitivity to lansoprazole or any of the inactive ingredients in the formulation (including sucrose or maize starch), you should not take this medication. Allergic reactions can range from mild skin rashes to severe anaphylaxis.
- Allergy to other PPIs: If you are allergic to other proton pump inhibitors (such as omeprazole, pantoprazole, rabeprazole, or esomeprazole), you may also react to lansoprazole due to cross-reactivity between drugs in this class. Inform your doctor if you have had a reaction to any PPI.
Warnings and Precautions
Speak with your healthcare provider before taking lansoprazole if any of the following apply to you. These situations require careful medical assessment and may necessitate dose adjustments or additional monitoring:
- Target-like red spots or circular patches on the trunk, often with blisters in the center, skin peeling, or sores in the mouth, throat, nose, or eyes — signs of Stevens-Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN)
- Widespread rash, high body temperature, and enlarged lymph nodes — possible drug reaction with eosinophilia and systemic symptoms (DRESS)
- Swelling of the face, tongue, or throat; difficulty swallowing; hives; or breathing difficulties — signs of angioedema
- Unexplained weight loss, persistent vomiting, difficulty swallowing, or vomiting blood — these may indicate a serious underlying condition that needs urgent investigation
- Severe liver disease: Lansoprazole is extensively metabolized by the liver. If you have severe hepatic impairment, your doctor may need to reduce your dose, as lansoprazole clearance is significantly reduced in patients with liver disease.
- Risk of Clostridioides difficile infection: PPI use, including lansoprazole, has been associated with a slightly increased risk of infectious diarrhea, particularly Clostridioides difficile (C. diff) infection. If you develop severe or persistent diarrhea during treatment, contact your healthcare provider immediately.
- Bone fracture risk: Long-term use of PPIs (especially at high doses and for more than one year) may increase the risk of osteoporosis-related fractures of the hip, wrist, or spine. Inform your doctor if you have osteoporosis or risk factors for bone loss, such as use of corticosteroids.
- Kidney inflammation: Acute interstitial nephritis (inflammation of the kidneys) has been reported with PPI use, including lansoprazole. Symptoms may include decreased urine output, blood in the urine, fever, rash, or joint stiffness. Report any such symptoms to your doctor promptly.
- Vitamin B12 deficiency: Long-term use of lansoprazole may lead to reduced absorption of vitamin B12 (cyanocobalamin). If you have pre-existing risk factors for B12 deficiency or are on long-term therapy, your doctor may monitor your B12 levels.
- Magnesium deficiency: Prolonged use (typically more than 3 months, but reported as early as 3 months) can cause hypomagnesemia (low blood magnesium), which may manifest as fatigue, muscle twitching, confusion, seizures, dizziness, or rapid heartbeat. Your doctor may check magnesium levels periodically.
- Skin reactions: If you develop a rash, particularly in sun-exposed areas, inform your doctor as you may need to discontinue treatment. Serious cutaneous adverse reactions (SCARs), including SJS, TEN, and DRESS, have been reported rarely.
- Blood test interference: Lansoprazole may affect chromogranin A (CgA) levels, which are used in diagnostic testing for neuroendocrine tumors. Inform your doctor if you are scheduled for CgA testing, as treatment should ideally be stopped at least 14 days before the test.
Pregnancy and Breastfeeding
If you are pregnant, breastfeeding, think you may be pregnant, or are planning to have a baby, consult your healthcare provider before taking lansoprazole. Lansoprazole is classified as FDA pregnancy category B, indicating that animal reproduction studies have not demonstrated fetal risk, but there are limited controlled studies in pregnant women. It should only be used during pregnancy if the potential benefit justifies the potential risk to the fetus.
Lansoprazole has been shown to be excreted in animal milk, and it is not known whether it is excreted in human breast milk. Because many drugs are excreted in human milk and because of the potential for adverse effects in nursing infants, a decision should be made whether to discontinue breastfeeding or discontinue the drug, taking into account the importance of the treatment to the mother. Always discuss the risks and benefits with your healthcare provider.
Driving and Operating Machinery
Lansoprazole may occasionally cause side effects such as dizziness, vertigo, fatigue, and visual disturbances. If you experience any of these effects, you should exercise caution when driving a car or operating machinery. You are responsible for assessing whether you are fit to drive or perform tasks that require alertness. Discuss any concerns with your doctor or pharmacist.
How Does Lansoprazole Interact with Other Drugs?
Lansoprazole can interact with several medications by altering stomach acid levels, affecting drug metabolism through liver enzymes (primarily CYP2C19 and CYP3A4), or changing the absorption of pH-dependent drugs. Always inform your doctor or pharmacist about all medications you are taking, including over-the-counter products and herbal supplements.
Drug interactions are an important consideration with any medication, and lansoprazole is no exception. Because it profoundly reduces stomach acid, lansoprazole can affect the absorption of medications that require an acidic environment to dissolve properly. Additionally, lansoprazole is metabolized by the liver enzymes CYP2C19 and CYP3A4, and can interact with other drugs that use these same metabolic pathways. Understanding these interactions helps you and your healthcare provider make informed decisions about your treatment plan.
Major Interactions
The following interactions are considered clinically significant and may require dose adjustments, alternative treatments, or close monitoring:
| Drug | Interaction | Clinical Significance |
|---|---|---|
| Methotrexate | PPIs may increase methotrexate serum levels by inhibiting its renal clearance | May cause methotrexate toxicity. Temporary withdrawal of lansoprazole may be needed with high-dose methotrexate |
| HIV protease inhibitors | Reduced absorption of certain HIV drugs (e.g., atazanavir, nelfinavir) due to increased gastric pH | Potential for HIV treatment failure and viral resistance. Avoid co-administration with some HIV drugs |
| Warfarin | Lansoprazole may increase INR and prothrombin time in patients taking warfarin | Increased bleeding risk. Monitor INR closely when starting, adjusting, or stopping lansoprazole |
| Tacrolimus | Lansoprazole may increase tacrolimus blood levels, particularly in CYP2C19 poor metabolizers | Risk of tacrolimus toxicity. Monitor blood levels closely, especially in transplant patients |
| Digoxin | Increased gastric pH may enhance digoxin absorption | Risk of digoxin toxicity. Monitor digoxin levels, particularly in patients on high doses |
Minor Interactions
The following interactions are generally less clinically significant but should still be noted and discussed with your healthcare provider:
| Drug | Interaction | Recommendation |
|---|---|---|
| Ketoconazole / Itraconazole | Reduced absorption due to increased gastric pH | Antifungal levels may be subtherapeutic; consider alternative antifungal agents |
| Theophylline | Lansoprazole may cause a modest reduction in theophylline clearance | Monitor theophylline levels when starting or stopping lansoprazole |
| Fluvoxamine | Fluvoxamine (CYP2C19 inhibitor) may substantially increase lansoprazole levels | Dose reduction of lansoprazole may be necessary |
| Sucralfate | Sucralfate may reduce absorption of lansoprazole | Take lansoprazole at least 30 minutes before sucralfate |
| Antacids | May reduce absorption of lansoprazole if taken simultaneously | Separate doses by at least 1 hour |
| Rifampicin | Rifampicin (CYP3A4 inducer) may reduce lansoprazole blood levels | Lansoprazole may be less effective; consider dose adjustment |
| St. John’s Wort | May reduce lansoprazole levels through CYP enzyme induction | Avoid concurrent use or discuss alternatives with your doctor |
For optimal absorption, lansoprazole should be taken at least 30 minutes before a meal with a glass of water. Food does not significantly affect the total amount absorbed but may delay peak plasma concentration. There are no specific restrictions regarding alcohol, but alcohol can worsen acid reflux symptoms and should be consumed in moderation.
What Is the Correct Dosage of Lansoprazole?
The dosage of lansoprazole depends on the condition being treated. For adults, typical doses are 15 mg or 30 mg once daily. Always take lansoprazole exactly as directed by your doctor or according to the package instructions for OTC use. Swallow capsules whole or use orally disintegrating tablets as directed.
Lansoprazole dosage varies depending on the specific condition being treated, its severity, and individual patient factors. Your healthcare provider will determine the most appropriate dose and duration of treatment for your situation. The following are the standard adult dosing recommendations based on international prescribing guidelines:
Adults
| Condition | Dose | Duration |
|---|---|---|
| Heartburn and acid reflux (OTC) | 15 mg or 30 mg once daily | Up to 4 weeks; consult doctor if no improvement |
| Duodenal ulcer | 30 mg once daily | 2 weeks (may be extended to 4 weeks) |
| Gastric ulcer | 30 mg once daily | 4 weeks (may be extended to 8 weeks) |
| Reflux esophagitis (treatment) | 30 mg once daily | 4 weeks (may be extended to 8 weeks) |
| Reflux esophagitis (prevention) | 15 mg once daily (may be increased to 30 mg) | Long-term as directed by doctor |
| H. pylori eradication | 30 mg twice daily with antibiotics | 7 days |
| NSAID-associated ulcer (treatment) | 30 mg once daily | 4 weeks |
| NSAID-associated ulcer (prevention) | 15 mg once daily (may be increased to 30 mg) | As long as NSAID therapy continues |
| Zollinger-Ellison syndrome | 60 mg once daily initially; adjust as needed | Individualized, long-term |
H. pylori antibiotic combinations: For eradication of Helicobacter pylori, lansoprazole 30 mg is typically given twice daily in combination with two antibiotics. The recommended regimens include:
- Lansoprazole 30 mg + clarithromycin 250–500 mg + amoxicillin 1,000 mg (all twice daily for 7 days)
- Lansoprazole 30 mg + clarithromycin 250 mg + metronidazole 400–500 mg (all twice daily for 7 days)
It is essential to complete the full course of antibiotic treatment to maximize the chance of successful H. pylori eradication and prevent antibiotic resistance.
Children
Lansoprazole is generally not recommended for use in children and adolescents unless specifically prescribed by a specialist physician. Pediatric use should be under the supervision of a healthcare provider experienced in treating children with gastrointestinal conditions. Dosing in children, when indicated, is typically based on body weight and the specific condition being treated.
Elderly
No routine dose adjustment is required for elderly patients. However, because elderly individuals may have reduced liver or kidney function, and may be taking multiple medications, their healthcare provider should consider the lowest effective dose and monitor for drug interactions and side effects more closely. Elderly patients are also at higher risk for PPI-associated fractures and should have their bone health monitored.
How to Take Lansoprazole
Proper administration of lansoprazole is important for its effectiveness:
- Timing: Take lansoprazole at the same time each day, preferably in the morning. If taking twice daily (for H. pylori), take the first dose in the morning and the second in the evening.
- Before meals: Take lansoprazole at least 30 minutes before eating for best results. This ensures the drug reaches peak levels when parietal cells are most active.
- Capsules: Swallow whole with a glass of water. Do not crush, chew, or open the capsules, as the enteric-coated granules inside must remain intact to protect the active ingredient from premature degradation by stomach acid.
- Orally disintegrating tablets (ODT): Place on the tongue and allow to dissolve without chewing. The tablet typically disintegrates within seconds. Swallow the resulting granules with or without water.
Missed Dose
If you forget to take a dose of lansoprazole, take it as soon as you remember, unless it is nearly time for your next scheduled dose. In that case, skip the missed dose and continue with your regular dosing schedule. Do not take a double dose to make up for a forgotten one. Setting an alarm or incorporating the medication into your daily routine (such as taking it with your morning preparation) can help prevent missed doses.
Overdose
If you take more lansoprazole than prescribed, or if a child accidentally ingests the medication, contact your local poison control center or seek emergency medical attention immediately. In clinical experience, overdose with lansoprazole has been reported rarely, and no specific symptoms of toxicity have been consistently identified at doses up to 180 mg. Treatment is symptomatic and supportive. Lansoprazole is not effectively removed by hemodialysis.
Even if your symptoms improve before completing the prescribed course, do not stop taking lansoprazole without consulting your doctor. Discontinuing treatment prematurely may result in incomplete healing and recurrence of your condition. For H. pylori treatment specifically, completing the full antibiotic course is critical for eradication success.
What Are the Side Effects of Lansoprazole?
Like all medications, lansoprazole can cause side effects, although not everyone experiences them. The most common side effects include headache, dizziness, nausea, diarrhea, constipation, and abdominal pain. Most side effects are mild and resolve on their own. Serious side effects are rare but include severe skin reactions, kidney inflammation, and severe allergic reactions.
Lansoprazole has been extensively studied in clinical trials and post-marketing surveillance. Most side effects are mild to moderate in severity and typically resolve after discontinuation of the medication. The following classification lists side effects according to their frequency of occurrence, based on data from clinical trials and regulatory reporting systems.
If you experience any serious side effects, or if mild side effects persist or worsen, contact your healthcare provider. It is especially important to seek immediate medical attention for signs of severe allergic reactions (angioedema, anaphylaxis), severe skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis, DRESS), or symptoms suggesting serious internal organ involvement.
Common
May affect up to 1 in 10 people
- Headache
- Dizziness
- Nausea, vomiting
- Diarrhea
- Abdominal pain or discomfort
- Constipation
- Flatulence (gas)
- Dry mouth or sore throat
- Benign gastric polyps (fundic gland polyps)
- Changes in liver function tests
- Skin rash or itching
- Fatigue
Uncommon
May affect up to 1 in 100 people
- Changes in blood cell counts (thrombocytopenia, eosinophilia)
- Depression
- Joint or muscle pain (arthralgia, myalgia)
- Fluid retention or edema (swelling)
Rare
May affect up to 1 in 1,000 people
- Anemia (pallor, fatigue)
- Insomnia, hallucinations, confusion
- Restlessness, vertigo, tingling sensations (paresthesia), drowsiness, tremor
- Visual disturbances
- Inflammation of the tongue (glossitis), candidiasis (oral thrush), pancreatitis
- Taste disturbances
- Hepatitis (liver inflammation), which may present as jaundice (yellowing of skin or eyes)
- Skin reactions: burning or stinging sensation, bruising, redness, hair loss, photosensitivity
- Kidney problems (interstitial nephritis)
- Breast swelling in men (gynecomastia)
- Fever, excessive sweating, angioedema, loss of appetite, impotence
Very Rare
May affect up to 1 in 10,000 people
- Severe reduction in white blood cells (agranulocytosis) — may increase susceptibility to infections
- Colitis (inflammation of the intestine)
- Stomatitis (inflammation of the mouth)
- Severe skin reactions: Stevens-Johnson syndrome, toxic epidermal necrolysis
- Severe hypersensitivity reactions including anaphylactic shock
- Changes in blood sodium, cholesterol, or triglyceride levels
Frequency Not Known
Cannot be estimated from available data
- Hypomagnesemia (low magnesium) — may occur after 3+ months of use, causing fatigue, muscle twitching, confusion, seizures, dizziness, or rapid heartbeat
- Hyponatremia (low sodium) — symptoms include nausea, vomiting, headache, drowsiness, confusion, muscle weakness or spasms, irritability, seizures
- Visual hallucinations
- Skin rash, possibly with joint pain (subacute cutaneous lupus erythematosus)
- Drug reaction with eosinophilia and systemic symptoms (DRESS)
Stop taking lansoprazole and seek emergency medical attention if you experience signs of a severe allergic reaction (swelling of the face, tongue, or throat; difficulty breathing; severe skin reactions) or if you notice symptoms of agranulocytosis (severe sore throat with high fever and marked general deterioration). These are medical emergencies that require urgent treatment.
How Should You Store Lansoprazole?
Store lansoprazole at room temperature (below 25°C / 77°F) in its original packaging. Keep it out of the reach and sight of children. Do not use the medication after the expiry date printed on the packaging. Protect from moisture — if using a bottle, close it tightly after each use.
Proper storage of lansoprazole is essential to maintain its effectiveness and safety throughout the shelf life. The enteric-coated granules within the capsules or orally disintegrating tablets are sensitive to moisture and should be protected accordingly.
- Temperature: Store at room temperature, not exceeding 25°C (77°F). Do not freeze.
- Blister packs: Keep in the original blister packaging until you are ready to take a dose. This protects the tablets from moisture and light.
- Bottles: Close the bottle tightly after each use. The product is moisture-sensitive. Once opened, the contents should be used within 4 months.
- Expiry date: Do not use lansoprazole after the expiry date stated on the packaging (the last day of the indicated month).
- Children: Keep all medications out of the sight and reach of children.
- Disposal: Do not dispose of unused medications via wastewater or household waste. Return unused medication to your pharmacy for proper disposal. This helps protect the environment.
What Does Lansoprazole Contain?
Each lansoprazole capsule contains either 15 mg or 30 mg of the active ingredient lansoprazole as enteric-coated granules. The capsules also contain various inactive ingredients that help with formulation, stability, and the enteric coating that protects the drug from stomach acid.
Understanding the full composition of your medication can be important, particularly if you have known allergies or intolerances to specific ingredients. The following information is based on typical formulations; specific products may vary slightly between manufacturers.
Active Ingredient
Lansoprazole — available in 15 mg and 30 mg strengths. Lansoprazole is a substituted benzimidazole that belongs to the proton pump inhibitor (PPI) class.
Inactive Ingredients (Excipients)
Typical inactive ingredients found in lansoprazole formulations include:
- Sugar spheres (sucrose and maize/corn starch)
- Povidone
- Disodium hydrogen phosphate dihydrate
- Sodium lauryl sulfate
- Sucrose
- Maize starch
- Methacrylic acid-ethyl acrylate copolymer (1:1) dispersion (enteric coating)
- Talc
- Macrogol (polyethylene glycol)
- Titanium dioxide (E171)
- Polysorbate 80
- Gelatin (capsule shell)
- Red iron oxide (E172) — in 15 mg capsules only
Lansoprazole capsules contain sucrose. If you have been told by your doctor that you have an intolerance to certain sugars, contact your healthcare provider before taking this medication. The product contains less than 1 mmol (23 mg) sodium per capsule and is therefore essentially sodium-free.
Appearance
- 15 mg capsules: White/red-brown gelatin capsules filled with white to light brown or pinkish enteric-coated granules
- 30 mg capsules: White gelatin capsules filled with white to light brown or pinkish enteric-coated granules
Frequently Asked Questions About Lansoprazole
Both lansoprazole and omeprazole are proton pump inhibitors (PPIs) that reduce stomach acid production through the same fundamental mechanism — irreversible inhibition of the H+/K+-ATPase proton pump. In clinical trials, both demonstrate similar efficacy for healing peptic ulcers and managing GERD. However, lansoprazole generally has higher oral bioavailability (over 80%) compared to omeprazole (30–40%), which means a greater proportion of the dose is absorbed. Lansoprazole is also available as an orally disintegrating tablet, which may be more convenient for patients who have difficulty swallowing. The choice between the two is often based on individual response, tolerability, availability, and cost.
While lansoprazole is effective and generally well-tolerated, long-term use (beyond 8 weeks) should be under medical supervision. Prolonged use has been associated with potential risks including magnesium deficiency, vitamin B12 deficiency, increased risk of bone fractures (hip, wrist, spine), and Clostridioides difficile infection. Your doctor should regularly review whether continued treatment is necessary, and the lowest effective dose should be used. For maintenance therapy of conditions like reflux esophagitis, the 15 mg dose is typically preferred to minimize long-term risks.
Place the orally disintegrating tablet (ODT) on your tongue and allow it to dissolve naturally without chewing. The tablet typically disintegrates within 30 seconds to 1 minute. You can then swallow the dissolved granules with or without water. Alternatively, the ODT can be dissolved in a small amount of water (approximately 15 mL) in a syringe and administered orally or through a nasogastric tube. Do not break, cut, or chew the tablet, as the enteric-coated microgranules must remain intact to protect the active ingredient from premature degradation in the stomach.
Lansoprazole is classified as FDA pregnancy category B, meaning animal studies have not demonstrated fetal harm, but there are limited well-controlled studies in pregnant women. It should only be used during pregnancy if clearly needed, and the potential benefits outweigh the potential risks. If you are pregnant, breastfeeding, planning to become pregnant, or suspect you may be pregnant, consult your healthcare provider before taking lansoprazole. They can help weigh the benefits and risks for your individual situation and may recommend alternative approaches if appropriate.
Lansoprazole begins to inhibit acid production within 1–2 hours of taking a dose. However, because it works by progressively blocking more proton pumps with each successive dose, it may take 2–3 days of regular daily use to achieve significant symptom relief. Maximum acid suppression is typically reached after 4–5 days of continuous once-daily dosing. For optimal results, take lansoprazole consistently at the same time each day, preferably 30 minutes before breakfast.
If you have been using lansoprazole for a short period (up to 14 days for OTC use), you can stop without tapering. However, after long-term use (more than 8 weeks), stopping abruptly can cause rebound acid hypersecretion — a temporary increase in stomach acid production above pre-treatment levels. This can lead to worsening heartburn, acid reflux, and discomfort. Your doctor may recommend gradually reducing the dose over several weeks to minimize rebound effects. Never discontinue prescribed treatment early without consulting your healthcare provider.
References
This article is based on the following peer-reviewed sources, international guidelines, and regulatory documents. All medical claims have evidence level 1A (systematic reviews and meta-analyses of randomized controlled trials) where available.
- European Medicines Agency (EMA). Lansoprazole — Summary of Product Characteristics (SmPC). EMA, 2024. Available at: www.ema.europa.eu
- U.S. Food and Drug Administration (FDA). Prevacid (lansoprazole) — Prescribing Information. FDA, 2024. Available at: www.fda.gov
- World Health Organization (WHO). WHO Model List of Essential Medicines — 23rd List, 2023. Geneva: WHO, 2023.
- British National Formulary (BNF). Lansoprazole Monograph. National Institute for Health and Care Excellence (NICE), 2025. Available at: bnf.nice.org.uk
- Malfertheiner P, Megraud F, Rokkas T, et al. Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report. Gut. 2022;71(9):1724–1762. doi:10.1136/gutjnl-2022-327745
- Freedberg DE, Kim LS, Yang YX. The Risks and Benefits of Long-term Use of Proton Pump Inhibitors: Expert Review and Best Practice Advice From the American Gastroenterological Association. Gastroenterology. 2017;152(4):706–715. doi:10.1053/j.gastro.2017.01.031
- Vaezi MF, Yang YX, Howden CW. Complications of Proton Pump Inhibitor Therapy. Gastroenterology. 2017;153(1):35–48. doi:10.1053/j.gastro.2017.04.047
- Moayyedi P, Eikelboom JW, Bosch J, et al. Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin. Gastroenterology. 2019;157(3):682–691.e2. doi:10.1053/j.gastro.2019.05.056
- NICE Clinical Knowledge Summaries. Dyspepsia — proven gastro-oesophageal reflux disease. National Institute for Health and Care Excellence, 2024.
- Scarpignato C, Gatta L, Zullo A, et al. Effective and safe proton pump inhibitor therapy in acid-related diseases — A position paper addressing benefits and potential harms of acid suppression. BMC Med. 2016;14(1):179. doi:10.1186/s12916-016-0718-z
Editorial Team
iMedic Medical Editorial Team — specialists in gastroenterology and clinical pharmacology with extensive experience in evidence-based drug information. Our team follows the GRADE evidence framework and international guidelines from WHO, EMA, FDA, and BNF.
iMedic Medical Review Board — an independent panel of board-certified physicians who review all content according to international medical standards. Each article undergoes rigorous fact-checking and clinical accuracy verification before publication.
- All content is evidence-based and follows the GRADE framework
- No commercial funding or pharmaceutical sponsorship
- Regular updates when new evidence or guidelines are published
- Transparent conflict-of-interest declarations
- Compliant with WCAG 2.2 Level AAA accessibility standards